Characterization of Hypoxia Signature to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Glioma Groups
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Glioma groups, including lower-grade glioma (LGG) and glioblastoma multiforme (GBM), are the most common primary brain tumor. Malignant gliomas, especially glioblastomas, are associated with a dismal prognosis. Hypoxia is a driver of the malignant phenotype in glioma groups; it triggers a cascade of immunosuppressive processes and malignant cellular responses (tumor progression, anti-apoptosis, and resistance to chemoradiotherapy), which result in disease progression and poor prognosis. However, approaches to determine the extent of hypoxia in the tumor microenvironment are still unclear. Here, we downloaded 575 LGG patients and 354 GBM patients from Chinese Glioma Genome Atlas (GGGA), and 530 LGG patients and 167 GBM patients from The Cancer Genome Atlas (TCGA) with RNA sequence and clinicopathological data. We developed a hypoxia risk model to reflect the immune microenvironment in glioma and predict prognosis. High hypoxia risk score was associated with poor prognosis and indicated an immunosuppressive microenvironment. Hypoxia signature significantly correlated with clinical and molecular features and could serve as an independent prognostic factor for glioma patients. Moreover, Gene Set Enrichment Analysis showed that gene sets associated with the high-risk group were involved in carcinogenesis and immunosuppression signaling. In conclusion, we developed and validated a hypoxia risk model, which served as an independent prognostic indicator and reflected overall immune response intensity in the glioma microenvironment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Goetz, M. P., Olson, J. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804710 · Cited by 2,397 · cited 1×
“For example, the 21-gene expression assay (Oncotype DX, Genomic Health) is one of several commercially available gene-expression assays that provide prognostic information in hormone-receptor–positive breast cancer (24).”
MethodThe role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy
Muz, B., de la Puente, P., Azab, F., & Azab, A. K. (2015) · Hypoxia · doi:10.2147/hp.s93413 · Cited by 2,066 · cited 3×
“Substantial data suggest that tumor hypoxia is involved in processes conferring a growth advantage to tumor cells and the development of a more malignant phenotype (2, 3).”
BackgroundRole of hypoxia in cancer therapy by regulating the tumor microenvironment
Jing, X., Yang, F., Shao, C., Wei, K., Xie, M., Shen, H., & Shu, Y. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1089-9 · Cited by 2,054 · cited 3×
“Substantial data suggest that tumor hypoxia is involved in processes conferring a growth advantage to tumor cells and the development of a more malignant phenotype (2, 3).”
BackgroundFates of CD8+ T cells in Tumor Microenvironment
Maimela, N. R., Liu, S., & Zhang, Y. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2018.11.004 · Cited by 459
Current status of interleukin-10 and regulatory T-cells in cancer
Dennis, K. L., Blatner, N. R., Gounari, F., & Khazaie, K. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000006 · Cited by 289 · cited 1×
“Interleukin-10 (IL-10), a key immune-suppressive cytokine secreted by M2-macrophages, Tregs and Th2-cells, has been shown to impair the proliferation, cytokine production, and migratory capacities of effector T cells (32).”
BackgroundTransforming growth factor-β: a therapeutic target for cancer
Haque, S., & Morris, J. C. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1327107 · Cited by 276
Hypoxia-induced PD-L1/PD-1 crosstalk impairs T-cell function in sleep apnoea
Cubillos-Zapata, C., Avendaño-Ortiz, J., Hernandez-Jimenez, E., Toledano, V., Casas-Martin, J., Varela-Serrano, A., Torres, M., Almendros, I., Casitas, R., Fernández-Navarro, I., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00833-2017 · Cited by 116
Cited by
Uti, D. E., Egbung, J. E., Anthony, B. O., Omari, O. R., Omang, W. A., Aggad, W. S., Almohaimeed, H. M., Bainsal, N., Shukla, S. K., Ealla, K. K. R., et al. (2026) · Discover Nano · doi:10.1186/s11671-026-04681-9 · Cited by 3
“Responsiveness to radiosensitization could be predicted by molecular biomarkers of ATM/ATR status, HIF-1 expression, PD-L1 levels as well as tumor-microenvironment immune composition [171, 172].”
Metadata
- Authors
- Lin, W., Wu, S., Chen, X., Ye, Y., Weng, Y., Pan, Y., Chen, Z., Chen, L., Qiu, X., & Qiu, S.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2020-05-15
- Volume
- 10
- Pages
- 796-796
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W3024542302
- Cited by
- 181
- References
- 8
- FWCI
- 16.18
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.